Last updated on November 7, 2025
No. In Bolivia, the distribution of pharmaceuticals without certification from AGEMED (Agencia Estatal de Medicamentos y Tecnologías en Salud) is strictly prohibited. AGEMED is the national regulatory authority responsible for authorizing, monitoring, and controlling all activities related to medicines, including importation, commercialization, and distribution. Every pharmaceutical product must obtain a sanitary registration and comply with national and international standards before entering the Bolivian market.
Why Certification Is Mandatory
Bolivia’s pharmaceutical regulations are designed to protect public health by ensuring that all medicines distributed in the country meet rigorous standards of safety, efficacy, and quality. The legal foundation for these rules is established under Law No. 1737 (Pharmaceutical Law) and related decrees, which mandate that no pharmaceutical product can be manufactured, imported, or marketed without prior approval from AGEMED.
AGEMED operates under the Ministry of Health and Sports and serves as the central authority for pharmaceutical oversight. Its role includes granting sanitary registrations, conducting inspections, and enforcing compliance with Good Manufacturing Practices (GMP). This system prevents counterfeit or substandard drugs from reaching consumers and aligns Bolivia with international health standards set by the World Health Organization (WHO).
The Legal Framework: What the Law Says
According to AGEMED guidelines and Supreme Decree 25235, all pharmaceutical products—whether generic, branded, or over-the-counter—must undergo a formal registration process. This process involves:
- Submission of a pharmacological monograph detailing the drug’s composition, dosage, indications, contraindications, and potential side effects.
- Presentation of three product samples for laboratory analysis at INLASA (Instituto Nacional de Laboratorios de Salud).
- Compliance with WHO and Pan-American Health Organization standards.
- Provision of certificates of origin and quality for imported products.
Without this certification, distribution is illegal and subject to penalties, including fines, seizure of goods, and suspension of operating licenses.
Why These Rules Exist
The Bolivian Constitution guarantees the right to health and access to safe medicines. Regulatory control ensures that products circulating in the market are effective and free from harmful substances. In a global context where counterfeit drugs pose serious risks, Bolivia’s strict certification system acts as a safeguard for public health.
Practical Implications for Distributors
Companies planning to distribute pharmaceuticals in Bolivia must:
- Register with AGEMED as an authorized importer or distributor.
- Obtain sanitary registration for each product before commercialization.
- Maintain compliance with Good Storage and Distribution Practices.
- Submit to periodic inspections and pharmacovigilance reporting.
Failure to comply can result in severe consequences, including criminal liability for public health violations.
Cultural and Economic Context
Bolivia’s pharmaceutical market relies heavily on imports due to limited local production. This makes regulatory oversight even more critical. By enforcing certification, AGEMED not only protects consumers but also fosters trust in the healthcare system and supports Bolivia’s commitment to international health agreements.
See more on BOLIVIA
Sources
Agencia Estatal de Medicamentos y Tecnologías en Salud – AGEMED
https://www.agemed.gob.bo/
Ongoing
Bolivia Drug Registration Process – Ministry of Health
https://www.minsalud.gob.bo/
Ongoing